Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice

Molecular Therapy

Volumn 17, Issue 2, 2009, Pages 253-261

  Bostick, Brian ^a   Yue, Yongping ^b   Long, Chun ^a   Marschalk, Nate ^a   Fine, Deborah M ^b   Chen, Jing ^a   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; DELTAH2 R19 MINI DYSTROPHIN; DOBUTAMINE; MYOSIN HEAVY CHAIN ALPHA; UNCLASSIFIED DRUG; DYSTROPHIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR GENE THERAPY; CONTROLLED STUDY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ELECTROCARDIOGRAM; FEMALE; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART STROKE VOLUME; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SARCOLEMMA; SYSTOLE; TRANSGENIC MOUSE; TREADMILL EXERCISE; WESTERN BLOTTING; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEART; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SOUTHERN BLOTTING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALIA; MUS;

ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; DYSTROPHIN; FLUORESCENT ANTIBODY TECHNIQUE; HEART; MICE; MICE, INBRED MDX; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOCARDIUM; POLYMERASE CHAIN REACTION;

EID: 63649114966     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.264     Document Type: Article

References (45)

1. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery (2005). Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 116: 1569-1573.
2. Baxter, P (2006). Treatment of the heart in Duchenne muscular dystrophy. Dev Med Child Neurol 48: 163.
3. Duan, D (2006). Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 15 (spec. 2): R253-R261.
4. Ervasti, JM (2007). Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 1772: 108-117.
5. Warner, LE, DelloRusso, C, Crawford, RW, Rybakova, IN, Patel, JR, Ervasti, JM et al. (2002). Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum Mol Genet 11: 1095-1105.
6. Crawford, GE, Faulkner, JA, Crosbie, RH, Campbell, KP, Froehner, SC and Chamberlain, JS (2000). Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 150: 1399-1410.
7. Li, S, Kimura, E, Ng, R, Fall, BM, Meuse, L, Reyes, M et al. (2006). A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum Mol Genet 15: 1610-1622.
8. Yue, Y, Liu, M and Duan, D (2006). C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knock-out mice. Mol Ther 14: 79-87.
9. Blankinship, MJ, Gregorevic, P and Chamberlain, JS (2006). Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated viral vectors. Mol Ther 13: 241-249.
10. Foster, K, Foster, H and Dickson, JG (2006). Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 13: 1677-1685.
11. England, SB, Nicholson, LV, Johnson, MA, Forrest, SM, Love, DR, Zubrzycka-Gaarn, EE et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343 180-182.
12. Harper, SQ, Hauser, MA, DelloRusso, C, Duan, D, Crawford, RW, Phelps, SF et al. (2002). Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8: 253-261.
13. Kasahara, H, Ueyama, T, Wakimoto, H, Liu, MK, Maguire, CT, Converso, KL et al. (2003). Nkx2.5 homeoprotein regulates expression of gap junction protein connexin 43 and sarcomere organization in postnatal cardiomyocytes. J Mol Cell Cardiol 35: 243-256.
14. Wei, L, Taffet, GE, Khoury, DS, Bo, J, Li, Y, Yatani, A et al. (2004). Disruption of Rho signaling results in progressive atrioventricular conduction defects while ventricular function remains preserved. FASEB J 18: 857-859.
15. Lim, BK, Xiong, D, Dorner, A, Youn, TJ, Yung, A, Liu, TI et al. (2008). Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart. J Clin Invest 118: 2758-2770.
16. Subramaniam, A, Jones, WK, Gulick, J, Wert, S, Neumann, J and Robbins, J (1991). Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 266: 24613-24620.
17. Bostick, B, Yue, Y, Long, C and Duan, D (2008). Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102: 121-130.
18. Bostick, B, Yue, Y, Lai, Y, Long, C, Li, D and Dongsheng, D (2008). AAV-9 micro-dystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 19: 851-856.
19. Danialou, G, Comtois, AS, Dudley, R, Karpati, G, Vincent, G, Des Rosiers, C et al. (2001). Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 15: 1655-1657.
20. Bernstein, D (2003). Exercise assessment of transgenic models of human cardiovascular disease. Physiol Genomics 13: 217-226.
21. Yue, Y, Li, Z, Harper, SQ, Davisson, RL, Chamberlain, JS and Duan, D (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108: 1626-1632.
22. Townsend, D, Blankinship, MJ, Allen, JM, Gregorevic, P, Chamberlain, JS and Metzger, JM (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 1086-1092.
23. Liu, M, Yue, Y, Harper, SQ, Grange, RW, Chamberlain, JS and Duan, D (2005). Adeno-associated virus-mediated micro-dystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 11: 245-256.
24. Lai, Y, Yue, Y, Liu, M, Ghosh, A, Engelhardt, JF, Chamberlain, JS et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 23: 1435-1439.
25. Badorff, C, Lee, GH, Lamphear, BJ, Martone, ME, Campbell, KP, Rhoads, RE et al. (1999). Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5: 320-326.
26. Wells, KE, Torelli, S, Lu, Q, Brown, SC, Partridge, T, Muntoni, F et al. (2003). Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle. Neuromuscul Disord 13: 21-31.
27. Torelli, S, Brown, SC, Jimenez-Mallebrera, C, Feng, L, Muntoni, F and Sewry, CA (2004). Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 30: 540-545.
28. Judge, LM, Haraguchi, M and Chamberlain, JS (2006). Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci 119: 1537-1546.
29. Thomas, GD, Sander, M, Lau, KS, Huang, PL, Stull, JT and Victor, RG (1998). Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci USA 95: 15090-15095.
30. Gnecchi-Ruscone, T, Taylor, J, Mercuri, E, Paternostro, G, Pogue, R, Bushby, K et al. (1999). Cardiomyopathy in Duchenne, Becker, and sarcoglycanopathies: A role for coronary dysfunction? Muscle Nerve 22: 1549-1556.
31. Ramaciotti, C, Iannaccone, ST and Scott, WA (2003). Myocardial cell damage in Duchenne muscular dystrophy. Pediatr Cardiol 24: 503-506.
32. Melacini, P, Fanin, M, Danieli, GA, Fasoli, G, Villanova, C, Angelini, C et al. (1993). Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 22: 1927-1934.
33. Nigro, G, Politano, L, Nigro, V, Petretta, VR and Comi, LI (1994). Mutation of dystrophin gene and cardiomyopathy. Neuromuscul Disord 4: 371-379.
34. Jefferies, JL, Eidem, BW, Belmont, JW, Craigen, WJ, Ware, SM, Fernbach, SD et al. (2005). Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 112: 2799-2804.
35. Cohen, N and Muntoni, F (2004). Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy. Heart 90: 835-841.
36. Towbin, JA, Hejtmancik, JF, Brink, P, Gelb, B, Zhu, XM, Chamberlain, JS et al. (1993). X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87: 1854-1865.
37. Megeney, LA, Kablar, B, Perry, RL, Ying, C, May, L and Rudnicki, MA (1999). Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 96: 220-225.
38. Hunsaker, RH, Fulkerson, PK, Barry, FJ, Lewis, RP, Leier, CV and Unverferth, DV (1982). Cardiac function in Duchenne's muscular dystrophy. Results of 10-year follow-up study and noninvasive tests. Am J Med 73: 235-238.
39. Takenaka, A, Yokota, M, Iwase, M, Miyaguchi, K, Hayashi, H and Saito, H (1993). Discrepancy between systolic and diastolic dysfunction of the left ventricle in patients with Duchenne muscular dystrophy. Eur Heart J 14: 669-676.
40. Nigro, G, Comi, LI, Politano, L, Limongelli, FM, Nigro, V, De Rimini, ML et al. (1995). Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve 18: 283-291.
41. van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer-Bout, M et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
42. Duan, D, Yue, Y, Zhou, W, Labed, B, Ritche, TC, Grosschedl, R et al. (1999). Submucosal gland development in the airway is controlled by lymphoid enhancer binding factor 1 (LEF1). Development 126: 4441-4453.
43. Yue, Y, Skimming, JW, Liu, M, Strawn, T and Duan, D (2004). Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet 13: 1669-1675.
44. Stegemann, H and Stalder, K (1967). Determination of hydroxyproline. Clin Chim Acta 18: 267-273.
45. Kregel, KC, Allen, DL, Booth, FW, Fleshner, MR, Henriksen, EJ, Musch, TL et al. (2006). Resource Book for the Design of Animal Exercise Protocols. American Physiological Society: Bethesda, MD.